French Biotech will work with the World’s Leader in Hearing Implants.
Sensorion and Cochlear will explore if a combination of a drug and a hearing implant can improve the treatment of hearing loss.
Based in the French city of Montpellier, Sensorion specializes in the development of treatments for inner ear disorders such as vertigo and hearing loss. The company’s technology received major recognition today with the announcement that Cochlear, the world’s leader in the hearing implant market, will collaborate with Sensorion to improve hearing loss treatment.
As part of the agreement, Sensorion will run preclinical trials with a combination of Sensorion’s drug candidate SENS-401 and Cochlear’s implants. Cochlear will invest €1.6M in shares of Sensorion, which is listed on Euronext Paris, in exchange for the right to be the first to negotiate with Sensorion the licensing of the drug to further develop the combination. Preclinical studies will start in 2018, and the combination might take it into Phase II clinical trials as soon as 2019.
To read the full article, visit Labiotech.eu
If you are experiencing hearing loss and aren’t sure where to begin with treatment, contact the Grey Bruce Audiology at 519-376-9084